top of page

Success Story

AOA Dx is at the forefront of developing a novel frontier in early-stage cancer detection for women, utilizing the power of glycolipids and their proprietary biomarker technology. Their GlycoLocate platform targets tumor marker gangliosides, advancing early cancer detection while also addressing a critical need by developing AKRIVIS GD, a liquid biopsy test designed for early-stage detection of ovarian cancer. W


Key milestones achieved in the past 12-18 months:  


-Raised $17M bringing total to $24M raised 

-Published paper in prestigious journal Frontiers of Oncology 

-Opened up US HQ in Denver, Colorado

-Started clinical trial 


The Eddies provided a great network of strong advisors, peers/founders to share insights, and industry introductions.

bottom of page